AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01717222
Drug: Intraperitoneal Lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 100 ml of 0.2% lignocaine
Trial: NCT01717222
Drug: Intravenous Lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
Trial: NCT00360568
Drug: Levodopa-carbidopa intestinal gel
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
Trial: NCT05555238
Drug: single arm, single group(No interventional)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Newvast® Tab, 10 to 80 mg daily administered per the locally approved product information)
Trial: NCT01275144
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01275144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03552991
Drug: Agiocur Pregranules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
Trial: NCT01656252
Drug: Phase II- Sequence B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag.
Trial: NCT01004055
Drug: ACTICOAT™ Antimicrobial Barrier Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing changes every 2-3 days, more frequently if needed
Trial: NCT03821701
Drug: ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choose one of ACEI/ARB according to the clinical condition among the whole study.
Trial: NCT03483259
Drug: Sulfatinib R capsule
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
Trial: NCT05148637
Drug: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
Trial: NCT02589145
Drug: Caphosol
RxNorm normalized name: Caphosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Trial: NCT02589145
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by vein or mouth three times a day from Day -1
Trial: NCT01423864
Drug: solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
Trial: NCT01673178
Drug: 50 mg PF-05231023
RxNorm normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg IV once a week for 4 weeks
Trial: NCT01673178
Drug: 100 mg PF-05231023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg IV once a week for 4 weeks
Trial: NCT01673178
Drug: 150 mg PF-05231023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg IV once a week for 4 weeks
Trial: NCT02874313
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment with oral antidiabetic drugs or insulin
Trial: NCT00004102
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004102
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004102
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01945983
Drug: Early norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
Trial: NCT01945983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
Trial: NCT03158168
Drug: Candida Antigen
RxNorm normalized name: Candida antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candida Albicans Antigen injection
Trial: NCT03158168
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc Sulfate injection
Trial: NCT00510614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one pill twice weekly for 12 weeks
Trial: NCT02819570
Drug: P.O roxithromycin 150 mg*2/d for 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02819570
Drug: P.O moxypen 500 mgx3/d for 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03896152
Drug: LNP023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: approximately 2 year of Treatment with LNP023
Trial: NCT02141620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01517295
Drug: Hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: Standard prescribed dose Frequency: Once Duration: Once
Trial: NCT03971383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets one time, 3 times a day(tid)
Trial: NCT02563834
Drug: thiapalmitate tracer
RxNorm normalized name: pyridoxine dipalmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabeled tracer infusion; occurs in all treatment arms
Trial: NCT00735007
Drug: Rebif® New Formulation (RNF) using RebiSmartTM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNF 44 mg, 3 times a week by subcutaneous injection.
Trial: NCT03179735
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Trial: NCT03775434
Drug: Experimental: B244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B244 suspension in 30ml/bottle
Trial: NCT03693326
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 300 mg (fixed dose) intraveneously every 3 weeks
Trial: NCT03814148
Drug: LENINGRADO 5 association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 coated sustained-release tablet, oral, once a day.
Trial: NCT03814148
Drug: Natrilix® SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 coated sustained-release tablet, oral, once a day.
Trial: NCT03179735
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Trial: NCT03044314
Drug: Iloprost and nitric oxide administration
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
Trial: NCT01310868
Drug: Gliadel wafers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
Trial: NCT03664115
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes
Trial: NCT01310868
Drug: Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
Trial: NCT00948649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
Trial: NCT01310868
Drug: Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
Trial: NCT00109551
Drug: iron sulphate-folic acid dietary supplement
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02546921
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
Trial: NCT04147260
Drug: Placebo to match BI 730357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT02700048
Drug: Intra-nasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
Trial: NCT00002535
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002535
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02743364
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00449163
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03706911
Drug: VM-1500A-LAI
RxNorm normalized name: laidlomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form
Trial: NCT02546921
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Trial: NCT02546921
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Trial: NCT00762684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
Trial: NCT01124747
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05867056
Drug: HBV HCC Module MAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose administration of IMC-I109V
Trial: NCT01409239
Drug: Subcutaneous Insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basal bolus insulin using carb counting technique and insulin analogues
Trial: NCT01845779
Drug: DCF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02343575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mg matched to VPA BID PO/NGT
Trial: NCT02546921
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Trial: NCT02546921
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Trial: NCT02546921
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Trial: NCT02546921
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
Trial: NCT00198991
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytostatic drug
Trial: NCT00198991
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytostatic drug
Trial: NCT00198991
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytostatic drug
Trial: NCT03767829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
Trial: NCT00591851
Drug: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC \[Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)\] Followed By Paclitaxel (P)
Trial: NCT00387946
Drug: SSR591813L (dianicline)
RxNorm normalized name: tetracycline hydrochloride Topical Ointment [Diabecline]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00259402
Drug: Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
Trial: NCT00847080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet per day per 2 weeks
Trial: NCT01227200
Drug: dypiron, tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dypiron 4 ML, tramadol 50 mg flashtab
Trial: NCT01318395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once per day
Trial: NCT00821717
Drug: Ferinject ® (Ferric carboxymaltose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).
Trial: NCT00814307
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg CP-690,550 BID PO for 6 months
Trial: NCT00198991
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antileukemic drug
Trial: NCT00814307
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg CP-690,550 BID PO for 6 months
Trial: NCT02420327
Drug: Placebo patch & placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
Trial: NCT00848939
Drug: treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
Trial: NCT00848939
Drug: treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
Trial: NCT00814307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
Trial: NCT00003489
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT04133909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
Trial: NCT02296333
Drug: isotonic
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg intravenous in the skin closure
Trial: NCT01717742
Drug: DNase
RxNorm normalized name: DNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
Trial: NCT04980014
Drug: NesinaAct® Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
Trial: NCT00431093
Drug: low-dose estradiol/noresterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time).